CUSIP 00032Q104COMWHWKQ4 2025
28 reported transactions
| # | Date | Insider | Title | Type | Shares | Price | Value | Held After | Filing |
|---|---|---|---|---|---|---|---|---|---|
| 1 | May 14, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER | A · Grant | 51.0K | $3.92 | $200.0K | 569.6K | SEC |
| 2 | May 14, 2026 | Dugan Margaret | Chief Medical Officer | A · Grant | 19.1K | $3.92 | $75.0K | 19.1K | SEC |
| 3 | May 14, 2026 | Ball Bryan | See remarks | A · Grant | 51.0K | $3.92 | $200.0K |
See the full Form 4 transaction history for Whitehawk Therapeutics Inc.
Unlock all transactions| 448.1K |
| SEC |
| 4 | May 14, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | A · Grant | 38.3K | $3.92 | $150.0K | 333.5K | SEC |
| 5 | May 14, 2026 | Castelein Caley | Director | A · Grant | 255.1K | $3.92 | $1.00M | 274.8K | SEC |
| 6 | May 14, 2026 | Castelein Caley | Director | A · Grant | 2.07M | $8124996.24 | $16.84T | 2.07M | SEC |
| 7 | May 12, 2026 | Avoro Capital Advisors LLC | Director | A · Grant | 6.38M | $3.92 | $25.00M | 14.71M | SEC |
| 8 | Apr 26, 2019 | Novartis Bioventures Ltd | 10% Owner | S · Sell | 138.7K | $1.03 | $142.9K | 4.05M | SEC |
| 9 | Apr 25, 2019 | Novartis Bioventures Ltd | 10% Owner | S · Sell | 563.1K | $1.03 | $580.0K | 4.19M | SEC |
| 10 | Apr 24, 2019 | Novartis Bioventures Ltd | 10% Owner | S · Sell | 16.4K | $1.03 | $16.9K | 4.75M | SEC |